Table 4. Empirical and subsequent antibiotic treatments (n = 381).
| Variables | Values | ||
|---|---|---|---|
| Empirical antibiotics during the first 48 hours | |||
| Carbapenem-based | 144 (38) | ||
| Extended-spectrum penicillin/β-lactamase inhibitor | 131 (34) | ||
| Glycopeptide or linezolid only | 20 (5) | ||
| Intravenous colistin-based | 19 (5) | ||
| Cefepime-based | 15 (4) | ||
| Tigecycline-based | 14 (4) | ||
| Quinolone only | 12 (3) | ||
| Third cephalosporin-based | 9 (2) | ||
| Carbapenem + tigecycline | 8 (2) | ||
| Sulbactam-based | 4 (1) | ||
| Intravenous colistin + tigecycline | 4 (1) | ||
| Others | 1 (0.3) | ||
| Combination therapy | |||
| Quinolone | 149/369 (40) | ||
| Glycopeptide or linezolid | 196/361 (54) | ||
| Inhaled colistin | 20 (5) | ||
| Subsequent antibiotics from the first 48 hour forth to 2 weeks | n = 377a | ||
| Carbapenem-based | 137 (36) | ||
| Extended-spectrum penicillin/β-lactamase inhibitor | 109 (29) | ||
| Intravenous colistin-based | 30 (8) | ||
| Intravenous colistin + tigecycline | 20 (5) | ||
| Cefepime-based | 19 (5) | ||
| Quinolone only | 15 (4) | ||
| Glycopeptide or linezolid only | 15 (4) | ||
| Tigecycline-based | 12 (3) | ||
| Third cephalosporin-based | 11 (3) | ||
| Carbapenem + tigecycline | 2 (1) | ||
| Sulbactam-based | 2 (1) | ||
| Others | 5 (1) | ||
| Combination therapy | |||
| Quinolone | 127 (34) | ||
| Glycopeptide or linezolid | 176 (47) | ||
Values are presented as number (%).
aFour patients with subsequent antibiotics from the first 48 hour forth to 2 weeks died.